Baxter signs definitive agreement to divest its biopharma solutions business to advent international and warburg pincus for $4.25 billion

Deerfield, ill. & boston & new york--(business wire)--baxter international inc. (nyse:bax), a leading global medtech company, today announced that it has signed a definitive agreement to divest its biopharma solutions (“bps”) business to advent international (“advent”), one of the largest and most experienced global private equity investors, and warburg pincus, a leading global growth investor. under the terms of the definitive agreement, baxter will receive $4.25 billion in cash, subject to ce.
BAX Ratings Summary
BAX Quant Ranking